enteroendocrine cells ͉ gastrointestinal chemosensation ͉ glucose sensor ͉ incretin G lucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins, peptide hormones secreted from enteroendocrine L and K cells, respectively, that augment insulin secretion after oral intake of glucose (1). How carbohydrates in the gut lumen elicit the release of GLP-1 from L cells and GIP from K cells is unknown (2). Because i.v. glucose administration does not induce secretion of GLP-1 (3) it appears that glucose within the lumen of the gut acts on the luminal surface to stimulate secretion. Thus, we sought to determine what glucose-sensing mechanism in the gut lumen might underlie this L cell response.
G
lucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretins, peptide hormones secreted from enteroendocrine L and K cells, respectively, that augment insulin secretion after oral intake of glucose (1) . How carbohydrates in the gut lumen elicit the release of GLP-1 from L cells and GIP from K cells is unknown (2) . Because i.v. glucose administration does not induce secretion of GLP-1 (3) it appears that glucose within the lumen of the gut acts on the luminal surface to stimulate secretion. Thus, we sought to determine what glucose-sensing mechanism in the gut lumen might underlie this L cell response.
One mechanism for sensing glucose is by sweet taste receptors in taste receptor cells of the lingual epithelium (4) . Sweet compounds bind to and activate specific G protein coupled receptors that couple through the G protein gustducin (5) to specific second messenger cascades (4, 6) . Two type 1 taste G protein coupled receptors (T1Rs) heterodimerize to form the T1R2ϩT1R3 sweet taste receptor (7) (8) (9) (10) (11) . Key elements of the taste transduction pathways are the ␣, ␤, and ␥ subunits of gustducin (␣-gustducin, G␤ 3 , and G␥ 13 ) (5, 12) , phospholipase C␤2 (PLC␤2) (13) , and transient receptor potential channel type M5 (14) , a Ca 2ϩ -activated cation channel (15) (16) (17) . ␣-Gustducin has been detected in brush cells of the stomach, duodenum, and pancreatic ducts in rat (18, 19) , T1R2 and T1R3 are present in rodent gut and the enteroendocrine STC-1 cell line (20) , and ␣-gustducin and GLP-1 are present in enteroendocrine cells of the human colon (21) . However, the functional significance of expression of taste signaling elements in cells of the gastrointestinal (GI) tract had been unclear. Here, we present data that indicate that T1R3 and gustducin have a role in glucosemediated incretin release and may serve as the previously unknown gut lumen glucose sensor.
Results
We examined L cells of the gut for the presence of taste receptors and elements of taste transduction pathways. In human duodenal biopsy sections ␣-gustducin was detected by immunofluores- . Several other taste signaling elements were also detected by IF in human duodenum: T1R2, T1R3, G␤ 3 , G␥ 13 , PLC␤2, and transient receptor potential channel type M5 ( Fig.  1 A and C) .
The numbers of cells per thousand nucleated epithelial cells (Fig. 1B Bottom) immunopositive for ␣-gustducin, 44 Ϯ 5, was higher than that of the entire GLP-1-expressing L cell population (15 Ϯ 2) (Fig. 1E) ; in addition, there were some ␣-gustducincontaining cells that did not stain for other components characteristic of L cells (data not shown). GIP was detected in 13 Ϯ 1 cells per 1,000 in the gut biopsies (Fig. 1E) , including some of the ␣-gustducin-containing cells (Fig. 1D ). More than 90% of human duodenal L cells contained ␣-gustducin, but Ͻ50% of K cells did so. Five to 10% of incretin cells in human duodenum contain both GIP and GLP-1 (''K/L'' cells) (22) , and those cells also contained ␣-gustducin (Fig. 1D) . However, some ␣-gustducincontaining cells did not appear to contain either peptide, consistent with their number per 1,000 nucleated epithelial cells being greater than the sum of L cells and K cells and suggesting that ␣-gustducin is present in at least one nonenterocyte intestinal cell subpopulation besides L and K cells.
To independently confirm the presence of ␣-gustducin in human enteroendocrine cells, human gut cells immunostained for GLP-1 or GIP were laser-captured and their RNA subjected to RT-PCR. Captured cells containing GIP or GLP-1 also expressed ␣-gustducin, whereas captured enterocytes were devoid of ␣-gustducin (Fig. 1F) .
Mouse duodenal GLP-1-containing cells also frequently expressed ␣-gustducin and ␣-gustducin promoter-driven GFP (12, 23) , along with GLP-2 and peptide YY typically present in L cells (SI Fig. 5 B and C) . This was also true for L cells of the mouse jejunum and ileum (SI Fig. 5 D and E) . In contrast to our results with human duodenum, mouse K cells rarely expressed ␣-gustducin.
To test whether gut-expressed ␣-gustducin plays a role in regulating postprandial secretion of GLP-1 and other gut hormones we gavage-administered glucose by feeding needles directly into the stomachs of homozygous mice lacking the gene for ␣-gustducin (␣-gust Ϫ/Ϫ ) (6) and of their wild-type (␣-gust ϩ/ϩ ) littermates, then compared their plasma concentrations of GLP-1, GIP, and insulin. In ␣-gust Ϫ/Ϫ mice, the ␣␤␥-gustducin heterotrimer does not form and therefore any signals mediated by gustducin or its coupled receptors are lost (24) . Plasma concentrations of GLP-1 in ␣-gust Ϫ/Ϫ mice did not rise in response to glucose ( Fig. 2A) . Rapid insulin secretion in response to glucose displayed by ␣-gust ϩ/ϩ mice was absent from ␣-gust Ϫ/Ϫ mice, although they eventually achieved peak insulin concentrations higher than those of ␣-gust ϩ/ϩ mice (Fig. 2 A) . Ten minutes after gavage-administration of glucose, GIP concentrations in ␣-gust Ϫ/Ϫ mice were greater than those in wildtype animals (Fig. 2 A) . For the next 30 min, the ␣-gust Ϫ/Ϫ mice maintained their GIP concentrations at a near constant level. In contrast, the wild-type mice showed a higher and more transient rise in GIP concentrations, peaking at 20 min after glucose administration. Glucose homeostasis was also altered in the ␣-gust Ϫ/Ϫ mice: plasma glucose concentrations after gavageadministration of glucose (Fig. 2B) or after eating lab chow following an 18h fast (Fig. 2C) were higher in the ␣-gust Ϫ/Ϫ mice than in their wild-type littermates, and were maintained at this elevated level for Ͼ2 h.
Thus, insulin secretion was deficient in ␣-gust Ϫ/Ϫ mice in response to glucose in the gut lumen; this deficit could be due to failure of either the glucose-sensing arm or the effector arm of the insulin secretory pathway. The ␣-gust Ϫ/Ϫ mice did increase insulin secretion in response to the GLP-1 receptor agonist exendin-4 or to i.p. administration of glucose (SI Fig. 6 A and B), indicating that GLP-1 receptors and glucose sensing in beta cells of the pancreas functioned normally in the absence of ␣-gustducin. We examined both L and K cell numbers and GLP-1 and GIP content in duodenum, jejunum, ileum, and colon of both sets of mice and found no significant differences in this regard between ␣-gust Ϫ/Ϫ and wild-type mice (data not shown). However, we did observe that the pancreatic islets from ␣-gust Ϫ/Ϫ mice were smaller than those from wild-type mice (SI Fig. 7 ), consistent with diminished trophic effects from one or more gut hormones.
Gavage-administration of glucose might stimulate ␣-gustducinexpressing brush cells of the stomach, depending on what receptors are expressed in these cells. Conceivably, these brush cells might contribute to duodenal release of GLP-1. To bypass such effects we examined GLP-1 secretion in ␣-gust Ϫ/Ϫ and ␣-gust ϩ/ϩ mice in which glucose was infused directly into the duodenum that had been isolated from the stomach and the rest of the small intestine, but remained in circulatory contact. In ␣-gust ϩ/ϩ mice plasma concentrations of GLP-1 peaked 10 min after duodenal infusion of 10% glucose, and then returned to baseline within 20 min (Fig. 2D ). In contrast, in ␣-gust Ϫ/Ϫ mice, plasma concentrations of GLP-1 did not increase. To further eliminate any other external effects that might affect release of GLP-1 from duodenal cells we harvested the proximal duodena of mice and then examined glucose-dependent release of GLP-1 from minced tissues and isolated villi. Culture medium with 10% glucose led to a greater increase in release of GLP-1 from duodenal tissue from ␣-gust ϩ/ϩ mice (Ϸ3.5-fold baseline) than it did in tissue from ␣-gust Ϫ/Ϫ mice (Ϸ2-fold baseline) (Fig. 2E ). Unstimulated amounts of GLP-1 secreted per gram of tissue ranged from 127 pg in ␣-gust ϩ/ϩ to 172 pg in ␣-gust Ϫ/Ϫ mice; glucose-stimulated amounts ranged from 445 pg in ␣-gust ϩ/ϩ to 322 pg in ␣-gust Ϫ/Ϫ mice. Similar differences were observed with release of GLP-1 from isolated villi in response to 5% glucose (see SI Fig. 6C and SI Fig. 8 for histology of the villi). Thus, the gustducin-dependent increase in GLP-1 release in vivo in response to luminal glucose appears to be intrinsic to the gustducin-expressing duodenal cells themselves. That glucose stimulated GLP-1 release from the tissue and villi of ␣-gust Ϫ/Ϫ mice indicates that one or more gustducin-independent mechanisms also contribute to this effect: possibilities include effects on L cell channels (e.g., closure of K ATP channels or transporter associated electrogenic currents), enhanced L cell metabolism, or sweet receptor coupling to other L cell-expressed G proteins.
By using IF microscopy and RT-PCR, we confirmed the expression of GLP-1 and peptide YY in NCI-H716 cells, a human enteroendocrine L cell line, and detected the presence in this cell line of several taste signaling elements: ␣-gustducin, G␤ 3 ; G␥ 13 ; PLC␤2; transient receptor potential channel type M5; T1R1; T1R2; T1R3; IP 3 type III receptor (IP 3 R-3); numerous phosphodiesterases (Pdes), including Pde1a, which has been described in taste cells (4); the fatty acid receptor Gpr40; and the bile acid receptor Tgr5 (25) (SI Fig. 9 A and B) . Stimulation of NCI-H716 cells with sucrose, glucose, or sucralose (a high potency noncaloric sweetener) led to a concentration-dependent release of GLP-1 into the medium (Fig. 3 A and B) . However, 2-deoxy-glucose, a nonmetabolizable nonsweet sugar used as a control for osmotic effects, did not increase GLP-1 release. Lactisole, a sweetness-antagonizing inhibitor of T1R3 (26), inhibited the sucralose-responsive release of GLP-1 (Fig. 3B) . We used siRNA to decrease expression of ␣-gustducin in NCI-H716 cells, and found diminished glucose-mediated GLP-1 secretion whereas basal secretion was unaffected (Fig. 3C) . Thus, T1R3 and gustducin are both implicated in mediating sweetener-induced GLP-1 secretion from NCI-H716 cells.
Release of GLP-1 from the mouse enteroendocrine cell line STC-1 in response to stimulation by free fatty acids correlates with increased phosphorylation of ERK (2). We found that phosphorylation of ERK in NCI-H716 cells was activated by glucose and sucralose, and inhibited by the sweet receptor antagonist lactisole or the ERK kinase inhibitor PD98059 (Fig.  3D) . Additionally, glucose-mediated GLP-1 secretion from NCI-H716 cells was inhibited by the phospholipase C inhibitor U73122 (SI Fig. 10 ).
Many taste stimuli elicit Ca 2ϩ release from internal stores or promote Ca 2ϩ entry or both (27, 28) . We therefore used single-cell imaging to monitor changes in the intracellular Ca indicator dye. Addition of glucose to the cells maintained in PBS led to an increase in [Ca 2ϩ ] i , whereas 2-deoxy-glucose had no such effect (SI Fig. 11 A-C) . The phospholipase C inhibitor U73122 inhibited glucose-stimulated Ca 2ϩ mobilization in NCI-H716 cells (SI Fig. 11 D) .
To examine functional coupling of taste receptors to G proteins in membranes from NCI-H716 cells we used the radioactive nonhydrolyzable GTP analog [
32 P] GTP-azidoanilide. In untreated control membranes there was constitutive GTPazidoanilide incorporation into G␣ i1,2 but not into ␣-gustducin or G␣ s (Fig. 4) . Treatment with glucose and sucrose led to a consistent increase in association of GTP-azidoanilide with ␣-gustducin and a decreased association with G␣ i1,2 (Fig. 4) . 
Discussion
The presence in enteroendocrine cells of functional gustducincoupled sweet taste receptors responsive to glucose identifies a new signaling mechanism to regulate intestinal hormone secretion. Our data indicate that glucose leads to secretion from L cells via a signaling pathway quite similar to that used by taste cells in the tongue, i.e., glucose activation of gustducin-coupled sweet receptors (T1R2ϩT1R3).
In vivo, ␣-gustducin null mice are defective for secretion of GLP-1 in response to luminal glucose. In vitro, isolated duodenum and duodenal villi from ␣-gustducin null mice likewise show deficient release of GLP-1 in response to glucose. In NCI-H716 enteroendocrine L cells, we observed G protein coupled receptormediated activation of ␣-gustducin by glucose and sucrose. Decreasing ␣-gustducin expression in NCI-H716 cells by siRNA resulted in decreased glucose-mediated GLP-1 secretion. In addition, the high potency sweetener sucralose induced GLP-1 secretion from NCI-H716 cells in a concentration-dependent manner, and this secretion of GLP-1 was inhibited by the sweet receptor inhibitor lactisole. These results confirm the involvement of ␣-gustducin coupled sweet receptors in sugar-and sweetener-stimulated secretion of GLP-1 from L cells.
The impression that there are many more L cells in the distal (ileum and colon) vs. proximal (duodenum and proximal jejunum) gut led to the suggestion that the early rapid rise of plasma GLP-1 after a glucose load was not from direct stimulation of the L cells. ''Proximal-to-distal'' models proposed that indirect neurally mediated signaling, initiated by glucose-sensing K cells or some other non-L cell of the proximal gut, leads to release of GLP-1 from L cells of the distal gut. However, contrary to this indirect neural model there is considerable evidence that luminal glucose directly leads to GLP-1 secretion from the proximal gut. First, although in humans there are more L cells in the gut distally than proximally, there are still many L cells in the duodenum and jejunum (22) . Second, the time course (onset, peak, and duration) of glucose-elicited release of GLP-1 in humans is consistent with the time course of glucose reaching the proximal intestine (29) (30) (31) (32) . Third, instilling small amounts of glucose solution by catheter into the duodenum in humans leads to increased plasma GLP-1 levels (33). Fourth, Roux-en-Y gastric bypass surgery leads to peak plasma levels of GLP-1 that are both higher and reached earlier than before bypass because of dumping of glucose directly into the jejunum (34). Fifth, many animal studies show that glucose directly stimulates GLP-1 secretion even in neurally isolated ileum preparations (35) . Finally, our studies with isolated tissues from wild-type and ␣-gust Ϫ/Ϫ mice strongly support a model in which direct sensing of glucose by taste signaling elements expressed in proximal L cells leads to GLP-1 release from these same proximal L cells.
GLP-1 receptor agonists and GLP-1 analogs are under intense investigation as treatments for type 2 diabetes and obesity. Exendin-4, an agonist of the GLP-1 receptor, has recently been approved for human use in type 2 diabetes because of its insulinotropic and weight-reducing properties. An alternative mode of modulating signaling through GLP-1 receptors would be to develop secretagogues to increase plasma levels of endogenous ligands, analogous to the use of sulfonylureas in increasing insulin secretion for the treatment of type 2 diabetes. It is now thought that the beneficial effects of Roux-en-Y bypass surgery on postprandial satiety, weight loss and diabetes are due, at least in part, to the increased GLP-1 and peptide YY secretion seen after such surgery (36) . If endogenous hormone levels of these peptides could be modulated, without serious anatomic and irreversible interventions such as Roux-en-Y bypass, it would be a major break-through in diabetes and obesity treatment. Sweeteners and secretagogues that increase plasma concentrations of endogenous GLP-1 may provide such an alternative means to promote GLP-1 receptor activity as a treatment for type 2 diabetes and obesity.
Materials and Methods IF and Confocal Microscopy.
The human paraffin-embedded duodenal sections (n ϭ 3) were from anonymous postmortem samples. Tissue processing and IF were performed as described in ref. 22 . For double immunofluorescent staining, sections were incubated overnight at 4°C with both primary antibodies (SI Table 1 ), washed, and incubated with secondary antibodies (Alexa 568 donkey anti-goat antibody for GLP-1, Alexa 488 donkey anti-rabbit antibody for others, and Cy3-conjugated goat anti-rabbit antibody for GLP-1 and GLP-2 in the gustducin-GFP mice) for 1 h, incubated with TOPRO-3 (Molecular Probes, Eugene, OR) for nuclear staining, washed, and mounted with fluorescence mounting medium, Vectashield (Vector Laboratories, Burlingame, CA). Images were acquired by using an inverted confocal microscope LSM-410 (Carl Zeiss MicroImaging, Thornwood, NY) with a 63ϫ oil-immersed objective and processed by using the MetaMorph software (Universal Imaging, Downingtown, PA). No fluorescent staining was observed when the primary antibody was omitted (SI Fig. 5 ). The NCI-H716 cells grown on coverslips were fixed in fresh 4% PFA in PBS for 10 min and permeabilized in 0.1% Triton X-100 in PBS for 10 min at room temperature. The cells were treated with blocking buffer (8% BSA in PBS) for 20 min, washed in PBS supplemented with 0.5% BSA and 0.05% Tween 20, and incubated with antibodies (SI Table 1 ) for 16 h at 4°C. After washing, cells were stained with Alexa Fluor secondary antibody as described above. Pancreata were fixed in 4% paraformaldehyde and embedded in paraffin, sections were incubated with antiguinea pig insulin antibody and stained with ABC/HRP (DakoCytomation, Carpinteria, CA), and islet diameter was quantified by using MetaMorph software, Version 4.6.3 (Universal Imaging). All methods are as described in ref. 37 .
Laser Capture Microdissection of Single Cells and PCR. Laser capture microdissection and image acquisition were performed as we described in ref. 22 . We designed human ␣-gustducin primers to amplify a 386-bp product (SI Table 2 ).
Animals. The design and production of ␣-gustducin null (␣-gust Ϫ/Ϫ ) mice (6) , and the mice expressing GFP from the 7.6-kb promoter region upstream from the ␣-gustducin gene (gustducin-GFP mice) are described in refs. 12, 23, and 24. The genetic background of all mice is C57BL/6. For comparisons of wild-type and ␣-gustducin null mice, ␣-gust ϩ/ϩ , ␣-gust ϩ/Ϫ , and ␣-gust Ϫ/Ϫ Fig. 4 . Coupling of taste receptors to G protein ␣-subunits in NCI-H716 cells.
Membranes from NCI-H716 cells were preincubated with the indicated concentrations of glucose and sucrose for 10min at 25°C in the presence of 5-10Ci [ 32 P] GTP-azidoanilide, then irradiated to cross link the GTP analog to G proteins. G protein-specific immune complexes (anti-G␣-gustducin, anti-G␣ i1,2, anti-G␣s, and control IgG) were separated by SDS/PAGE, transferred to membranes, and autoradiographically imaged. A positive control for G protein activation is shown in SI Fig. 12 .
littermate mice were generated from ␣-gust ϩ/Ϫ ϫ ␣-gust ϩ/Ϫ matings.
Gavage Administration of Glucose Load in Wild-Type and Transgenic
Mice. We carried out gastric gavages of glucose (2-5g/kg body weight) on fasted 8-week-old, wild-type, and ␣-gustducin null mice (n ϭ 7-12 animals per group). Gavage administration of glucose was by syringe attached to feeding needles (20 gauge ϫ 1 1 ͞2 ; Popper and Sons, New Hyde Park, NY) inserted through the mouth into the stomach. Blood samples (100 l) to which was added dipeptidyl peptidase IV inhibitor (Linco Research, Billerica, MA; 10 l/ml blood), were obtained before gavage (time 0) and 10, 20, and 40 min after gavage for determination of blood glucose by Glucometer Elite (Bayer, Emeryville, CA), plasma insulin by ELISA (Crystal Chem, Downers Grove, IL), and plasma N-terminal GLP-1 and total GIP by ELISA (Linco Research).
Tissue Measurements of Incretin Levels. GLP-1 and GIP content of duodenum, jejunum, ileum, and colon were measured in extracts of wild-type (n ϭ 5) and ␣-gustducin null mice (n ϭ 5) as described in refs. 38 and 39.
Blood Glucose in Wild-Type and Transgenic Mice After Alimentation.
Wild-type and ␣-gustducin null mice (n ϭ 6 animals per group) were fasted for 18 h and then allowed access to their regular food (Picolab rodent diet 20; Purina Mills, St. Louis, MO; catalog no. 5053) ad libitum. The blood glucose concentration was measured from tail vein samples, using a freestyle glucometer (Therasense, Alameda, CA); measurements were taken immediately before feeding (time 0) and 15, 30, 45, 60, 90, and 120 min after feeding.
Secretion of GLP-1 from Intact Duodenum in Vivo.
Wild-type and ␣-gustducin null mice (n ϭ 12) were fasted overnight and anesthetized by intraperitioneal injection of avertin (2-2-2 tribromoethanol, 250 mg/kg). Median laparotomy was performed. The duodenum was physically isolated from the stomach and rest of the intestinal tract by clamps placed at the gastroduodenal junction and within the duodenum Ϸ5 cm distal to the gastroduodenal junction. Care was taken to maintain circulatory contact. Glucose (10%) was injected directly into the lumen of the duodenum. Blood samples were collected from the posterior vena cava before glucose infusion and at 10 and 20 min after glucose infusion. Dipeptidyl peptidase IV inhibitor was added to the blood samples, and plasma GLP-1 was measured.
Secretion of GLP-1 from Minced Duodenum and Duodenal Villi. To acquire the duodenum for mincing, median laparotomy was done as above, then an incision was made in the antimesenteric side of the duodenum near the gastroduodenal junction, and the duodenum was flushed with 20 ml of HBSS (calcium-and magnesium-free). The proximal 5 cm of duodenum was dissected out, the serosal layer stripped off, then minced pieces of tissue (Ϸ1-2 mm 2 ) were placed in culture medium (40) (DMEM with or without 10% glucose with 10% FBS, 100 units/ml penicillin/ 100 mg/ml streptomycin/20 l/ml dipeptidyl peptidase IV inhibitor). Tissues were incubated in 5% CO 2 for 1 h at 37°C, the media was collected and GLP-1 levels assayed to determine unstimulated (baseline control) levels and that released into media. At the completion of the experiment cell viability was confirmed by exclusion of trypan blue. Duodenal villi were obtained from the proximal duodenum by scraping with mild pressure from the short edge of a glass slide. The isolated tissue was allowed to settle at the bottom of a tube on ice and then was washed 3 times with HBSS. After the final wash purified villi were resuspended in DMEM as above for minced tissue, aliquoted, and incubated as above but with 5% glucose to determine GLP-1 release. Calcium Imaging. Levels of [Ca 2ϩ ] i were quantified by fluorescence imaging, using the calcium indicator dye fura-2 as described in ref. 9 . Briefly, cells were incubated for 30min in the presence of 2 M acetoxymethylester form of fura-2 (Molecular Probes) and then washed twice in PBS (pH 7.4, without Ca 2ϩ ; Invitrogen) and allowed to incubate an additional 20-30min for complete deesterification of the dye. Cells were imaged on a Zeiss Axiovert microscope (40ϫ oil immersion objective) coupled to an Attofluor imaging system. The average [Ca 2ϩ ] i in 20-30 cells per microscope field was quantified in four separate cultures per treatment condition.
Immunoblotting. Western blot analysis was performed as described in ref. 36 . Detection of individual proteins was performed by immunoblotting with the primary antibodies, pErk (1:1,000; Cell Signaling, Danvers, MA) and total Erk (1:5,000; Santa Cruz Biotechnology, Santa Cruz, CA) and visualized by ECL. PD98059 was from Calbiochem.
Membrane Preparation, Labeling, and Immunoprecipitation of Membrane-Associated G Proteins. Cell membranes were purified and labeled as described in ref. 36 . [ 32 P] GTP-azidoanilide was from ALT Bioscience (Lexington, KY). The clarified supernatants (160 l) were transferred to tubes containing 5-10 l of polyclonal rabbit antisera raised against G␣-gustducin, G␣ s (Santa Cruz Biotechnology), and G␣ i1,2 (Affinity BioReagents, Golden, CO). Immunoprecipitation was performed as described in ref. 42 . A 20-l aliquot of the samples was subjected to SDS/PAGE. Gels were transferred to membrane, and band intensity was quantified by electronic autoradiography, using a Storm (Molecular Dynamics, Sunnyvale, CA). The protein concentration was determined by the Bradford method.
Statistical Analysis. GLP-1 data represent means Ϯ SEM. Differences between mean values for variables within individual experiments were compared statistically by ANOVA and followed by post hoc testing with Scheffé's test. Comparisons were performed by using Graphpad Prism (GraphPad Software, San Diego, CA). P Ͻ 0.05 was viewed as significant.
